Bone marrow aspiration, injection of cells
ProcedureBone marrow is aspirated at patients in all arms.
Arm "TNC" receives injection of total nucleated cells into ischemic muscle
NCT Number: NCT00753025
The purpose of this study is to determine whether autologous bone marrow derived cells and isolated CD133+ fraction are effective in the treatment limb ischemia
Looking for future studies?
Notify Me39 year–70 year
Male
Interventional
Phase 2
The number of patients with low limb obliterating atherosclerosis steadily grows and compounds more than 20-25 % from all kinds of a cardiovascular pathology. At conservation of this tendency to 2020 the amputation percentage executed due to vessel diseases, can reach 45 %. Hemodynamics improvement in an extremity by surgery is possible at 40 - 70 % of patients even with the widespread and plural lesion of arteries, but results are not always satisfactory. The most actual is the problem of angiosurgical help to patients with distal forms of arterial occlusions, due to the difficulty or impossibility performing reconstructive interventions. In these cases the operations of an indirect revascularization referred on stimulation of a collateral blood flow are carried out. However, despite the reached successes, in some cases results of such interventions do not give desirable effect, search of new methods of treatment therefore is necessary. To date the most perspective methods of neoangiogenesis stimulation are a cellular therapy and gene-engineering technologies. Experimental researches on a model of local limb ischemia showed possibility of use of various cells for neoangiogenesis stimulation. A number of clinical researches at patients with obliterating limb diseases has shown efficacy of cellular therapy even at a critical ischemia. However randomized, the placebo-controlled researches based on principles of evidence based medicine while it is not enough for the convincing conclusions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bone marrow is aspirated at patients in all arms.
Arm "TNC" receives injection of total nucleated cells into ischemic muscle
arm "CD133" receives injection of isolated CD 133+ cells
arm "placebo" receives injection of saline
Time frame: Within the first 30 days, 6 months and 12 months after injection
Clinical Center of Cellular Technologies, Russia
Other Gov
Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00962897
Arterial Occlusive Diseases, Arteriosclerosis
Dallas, Texas, United States
View Trial DetailsNCT00693823
Arterial Occlusive Diseases, Arteriosclerosis
Dallas, Texas, United States
View Trial DetailsNCT04912323
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial DetailsNCT00527475
Eye Diseases, Macular Degeneration
Santa Barbara, California, United States
View Trial Details